
eTable. Number of Delirium Symptom Score (NuDESC items 2, 3, 4) Observations Prior to Each Dose by Group
eFigure 1. MDAS Scores (Delirium Severity) Over the Study Period by Study Arm
eFigure 2. Mean Dose Administered During Study period by Study Arm for the 2 Age Groups

This supplementary material has been provided by the authors to give readers additional information about their work.
**eTable.** Number of Delirium Symptom Score (NuDESC items 2, 3, 4)

Observations Prior to Each Dose by Group

<table>
<thead>
<tr>
<th>Group</th>
<th>Eligibility (mean, SD)</th>
<th>Before Dose 1 (Baseline)</th>
<th>Before dose 2 (Baseline)</th>
<th>Before dose 3 (Baseline)</th>
<th>Before dose 4 (Baseline)</th>
<th>Before dose 5 (Baseline)</th>
<th>Before dose 6 (Baseline)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo n</td>
<td>82 (2.54, 1.43)</td>
<td>78 (2.10, 1.28)</td>
<td>72 (1.31, 1.37)</td>
<td>68 (0.96, 1.15)</td>
<td>68 (0.89, 1.08)</td>
<td>64 (0.70, 1.00)</td>
<td>64 (0.71, 1.25)</td>
</tr>
<tr>
<td>Risperidone n (mean, SD)</td>
<td>80 (2.54, 1.23)</td>
<td>78 (2.25, 1.31)</td>
<td>67 (1.93, 1.39)</td>
<td>61 (1.72, 1.47)</td>
<td>59 (1.64, 1.45)</td>
<td>47 (1.55, 1.65)</td>
<td>46 (1.26, 1.37)</td>
</tr>
<tr>
<td>Haloperidol n (mean, SD)</td>
<td>81 (2.60, 1.48)</td>
<td>79 (2.20, 1.34)</td>
<td>73 (1.60, 1.50)</td>
<td>65 (1.30, 1.27)</td>
<td>66 (1.20, 1.32)</td>
<td>59 (1.19, 1.18)</td>
<td>59 (1.29, 1.33)</td>
</tr>
</tbody>
</table>
**eFigure 1.** MDAS Scores (Delirium Severity) Over the Study Period by Study Arm

![Graph showing MDAS scores over the study period for different study arms: Placebo vs. Risperidone p = 0.01, Placebo vs. Haloperidol p = 0.015. Error bars represent 95% CI, and the model is adjusted for covariates in Table 2.](image-url)
**eFigure 2.** Mean Dose Administered During Study period by Study Arm for the 2 Age Groups

A  Patients older than 65 years

B  Patients 65 years or younger